PROCEPT BioRobotics Corporation logo PRCT - PROCEPT BioRobotics Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 3
SELL 1
STRONG
SELL 0
| PRICE TARGET: $42.40 DETAILS
HIGH: $62.00
LOW: $30.00
MEDIAN: $35.00
CONSENSUS: $42.40
UPSIDE: 46.21%

Stock News

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with prostate volumes 30–80 mL.

May 14, 2026 04:00 AM • globenewswire.com
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On Februa.

Apr 22, 2026 01:00 PM • businesswire.com (Hide legal announcements)
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PROCEPT BIOROBOTICS CORPORATION (PRCT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss.

Apr 22, 2026 11:00 AM • businesswire.com (Hide legal announcements)
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 25, 2026, Procept reported f.

Apr 22, 2026 10:07 AM • businesswire.com (Hide legal announcements)
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026

PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Apr 09, 2026 12:05 PM • globenewswire.com
Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)

Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)

OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares OPKO

Apr 05, 2026 09:40 PM • defenseworld.net
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.

Apr 01, 2026 05:00 AM • prnewswire.com (Hide legal announcements)
Procept BioRobotics: An Undervalued Surgical Robotics Growth Story

Procept BioRobotics: An Undervalued Surgical Robotics Growth Story

PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins. A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.

Mar 30, 2026 03:29 AM • seekingalpha.com
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, March 25, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.

Mar 25, 2026 05:00 AM • prnewswire.com (Hide legal announcements)

Price Targets